|
|
|
Volumn 72, Issue 2, 2000, Pages 200-205
|
|
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan adult leukemia study group (JALSG): Results of an interim analysis
|
|
Author keywords
Acute myeloid leukemia; Cytarabine; High risk mds; Idarubicin; Myelodysplastic syndrome
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTARABINE;
IDARUBICIN;
ACUTE DISEASE;
ADULT;
AGE;
AGED;
ARTICLE;
BONE MARROW;
CLINICAL TRIAL;
FEMALE;
HUMAN;
JAPAN;
KARYOTYPING;
MALE;
METHODOLOGY;
MIDDLE AGED;
MORTALITY;
MULTICENTER STUDY;
MYELODYSPLASTIC SYNDROME;
MYELOID LEUKEMIA;
PATHOLOGY;
REMISSION;
RISK FACTOR;
SURVIVAL RATE;
ACUTE DISEASE;
ADULT;
AGE FACTORS;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BONE MARROW;
CYTARABINE;
FEMALE;
HUMANS;
IDARUBICIN;
JAPAN;
KARYOTYPING;
LEUKEMIA, MYELOID;
MALE;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROMES;
REMISSION INDUCTION;
RISK FACTORS;
SURVIVAL RATE;
|
|
EID: 0034241197
PISSN: 09255710
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (8)
|
|
References (3)
|
